191 related articles for article (PubMed ID: 10848630)
1. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.
Qiu L; Burgess A; Fairlie DP; Leonard H; Parsons PG; Gabrielli BG
Mol Biol Cell; 2000 Jun; 11(6):2069-83. PubMed ID: 10848630
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints.
Warrener R; Beamish H; Burgess A; Waterhouse NJ; Giles N; Fairlie D; Gabrielli B
FASEB J; 2003 Aug; 17(11):1550-2. PubMed ID: 12824307
[TBL] [Abstract][Full Text] [Related]
3. Analysis of checkpoint responses to histone deacetylase inhibitors.
Beamish H; Warrener R; Gabrielli BG
Methods Mol Biol; 2004; 281():245-59. PubMed ID: 15220534
[TBL] [Abstract][Full Text] [Related]
4. The EBNA-3 gene family proteins disrupt the G2/M checkpoint.
Krauer KG; Burgess A; Buck M; Flanagan J; Sculley TB; Gabrielli B
Oncogene; 2004 Feb; 23(7):1342-53. PubMed ID: 14716295
[TBL] [Abstract][Full Text] [Related]
5. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner.
Noh EJ; Lim DS; Jeong G; Lee JS
Biochem Biophys Res Commun; 2009 Jan; 378(3):326-31. PubMed ID: 19038231
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death.
Nome RV; Bratland A; Harman G; Fodstad O; Andersson Y; Ree AH
Mol Cancer Ther; 2005 Aug; 4(8):1231-8. PubMed ID: 16093439
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of type I histone deacetylase increases resistance of checkpoint-deficient cells to genotoxic agents through mitotic delay.
Alao JP; Olesch J; Sunnerhagen P
Mol Cancer Ther; 2009 Sep; 8(9):2606-15. PubMed ID: 19723888
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
Li F; Wang T; Wang Z; Chen X; Liu R
Mol Med Rep; 2017 Nov; 16(5):6094-6101. PubMed ID: 28849080
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity.
Burgess AJ; Pavey S; Warrener R; Hunter LJ; Piva TJ; Musgrove EA; Saunders N; Parsons PG; Gabrielli BG
Mol Pharmacol; 2001 Oct; 60(4):828-37. PubMed ID: 11562446
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
11. Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Jain CK; Roychoudhury S; Majumder HK
Biochim Biophys Acta; 2015 May; 1853(5):1195-204. PubMed ID: 25746763
[TBL] [Abstract][Full Text] [Related]
12. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
[TBL] [Abstract][Full Text] [Related]
13. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation.
Shin HJ; Baek KH; Jeon AH; Kim SJ; Jang KL; Sung YC; Kim CM; Lee CW
Oncogene; 2003 Jun; 22(25):3853-8. PubMed ID: 12813458
[TBL] [Abstract][Full Text] [Related]
15. Induction of hRAD9 is required for G2/M checkpoint signal transduction in gastric cancer cells.
Hayashi K; Kuniyasu H; Oue N; Shigeishi H; Kuraoka K; Nakayama H; Yasui W
Pathobiology; 2002; 70(1):40-6. PubMed ID: 12415191
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle specific changes in the human cyclin B1 gene regulatory region as revealed by response to trichostatin A.
Katula KS; Fields A; Apple P; Rotruck T
Arch Biochem Biophys; 2002 May; 401(2):271-6. PubMed ID: 12054478
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Liu X; Guo Y; Li Y; Jiang Y; Chubb S; Azuma A; Huang P; Matsuda A; Hittelman W; Plunkett W
Cancer Res; 2005 Aug; 65(15):6874-81. PubMed ID: 16061671
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins.
Ouwehand K; de Ruijter AJ; van Bree C; Caron HN; van Kuilenburg AB
FEBS Lett; 2005 Feb; 579(6):1523-8. PubMed ID: 15733867
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Tse AN; Schwartz GK
Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
[TBL] [Abstract][Full Text] [Related]
20. Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis.
Wetzel M; Premkumar DR; Arnold B; Pollack IF
J Neurosurg; 2005 Dec; 103(6 Suppl):549-56. PubMed ID: 16383255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
